Aptose Biosciences Inc (APTO)

[Tartiaboy]

Totally agree. My biggest criticism is the lack of urgency. He is so focused on dotting the "i"s and crossing the "t"s for monotherapy that we are facing financial/dilution risks. APTO is finally getting to initial combination studies.

I believe that G1 Lux + venetoclax would have shown significant ORR results at the 750/900mg levels and that would have helped market perception. I agree with movement to G3 as the final formulation, but that doesn't mean we could not have had some combination data.

Many CEOs never waste time trying to get a monotherapy approval. I think he believes it's the fastest path to approval, but that's a risk. Combinations are much more likely to show clear efficacy-IMO.